Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.72 |
| ▸ | EGFR | P00533 | 10/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12107926 | 1.00 | METTL3 (0.72) | METTL3EGFRTSHRHIF1ATP53 | |
| SCHEMBL1300242 | 1.00 | METTL3 (0.72) | METTL3EGFRTSHRHIF1ATP53 | |
| SCHEMBL1300544 | 0.93 | METTL3 (0.62) | METTL3EGFRTSHRHIF1ATP53 | |
| SCHEMBL12107939 | 0.93 | METTL3 (0.62) | METTL3EGFRTSHRHIF1ATP53 | |
| SCHEMBL12107831 | 0.93 | METTL3 (0.62) | METTL3EGFRTP53POLBRXFP1 | |
| SCHEMBL13771368 | 0.93 | METTL3 (0.62) | METTL3EGFR | |
| SCHEMBL12107935 | 0.92 | METTL3 (0.64) | METTL3EGFRTSHRHIF1ATP53 | |
| SCHEMBL12107968 | 0.91 | METTL3 (0.61) | METTL3EGFRTSHRHIF1ATP53 | |
| SCHEMBL12108084 | 0.90 | METTL3 (0.69) | METTL3TSHRHIF1ATHRB | |
| SCHEMBL1301600 | 0.90 | METTL3 (0.60) | METTL3EGFRTSHRHIF1ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | claimed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | claimed |
| EP-2231665-A2 | NOVEL COMPOSITIONS AND METHODS OF USE | Ardea Biosciences, Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009089263-A2 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES INC. (US) | 2009-07-16 | — | — | WO | claimed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885EGFR 4552/4885TSHR 4868/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885EGFR 4552/4885TSHR 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.